References
- KudoMImanakaKChidaNPhase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinomaEur J Cancer201147142117212721664811
- LencioniRLlovetJMHanGSorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trialJ Hepatol20166451090109826809111
- MeyerTFoxRMaYTSorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trialLancet Gastroenterol Hepatol20172856557528648803
- KudoMUeshimaKIkedaMRandomized, open label, mul-ticenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trialJ Clin Oncol201836suppl 4S; abstr 206 Available from: https://meetinglibrary.asco.org/record/155728/abstractAccessed September 13, 2018
- LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
- ChengALKangYKChenZEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialLancet Oncol2009101253419095497
- YoonSMLeeSJKimJHEffect of transarterial chemoembolization plus external beam radiotherapy on survival of patients with hepatocellular carcinoma showing macroscopic vascular invasion compared with sorafenib: A randomized trialJ Clin Oncol201836suppl 4S; abstr 210 Available from: https://meetinglibrary.asco.org/record/156725/abstractAccessed September 14, 2018
- BruixJQinSMerlePRegorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialLancet201738910064566627932229
- KelleyRKVerslypeCCohnALCabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation studyAnn Oncol201728352853428426123
- Abou-AlfaGKMeyerTChengALCabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trialJ Clin Oncol201836suppl 4S; abstr 207 Available from: https://meetinglibrary.asco.org/record/155732/abstractAccessed September 14, 2018
- El-KhoueiryABSangroBYauTNivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialLancet2017389100882492250228434648
- WainbergZASegalNHJaegerDSafety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC)J Clin Oncol201735 suppl; abstr 4071
- ZhuAXFinnRSCattanSKEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenibJ Clin Oncol201836suppl 4S; abstr 209 Available from: https://meetinglibrary.asco.org/record/155743/abstractAccessed September 14, 2018